Comparative Pharmacology
Head-to-head clinical analysis: TEXACORT versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEXACORT versus TRIACORT.
TEXACORT vs TRIACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
10-20 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid